comparemela.com

Latest Breaking News On - Advanced clinical research center - Page 1 : comparemela.com

JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Hamburg
Germany
Kyoto
Japan
Rio-grande-do-sul
Brazil
Eppendorf
Nordrhein-westfalen
Sao-paulo
Sãpaulo
Kanagawa

JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders – IT Business Net

JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United-states
Sao-paulo
Sãpaulo
Brazil
Hamburg
Germany
Canada
Hyogo
Hokkaido
Japan
Kanagawa
Fukushima

JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders | Region

HYOGO, Japan (BUSINESS WIRE) Feb 14, 2024

Eppendorf
Nordrhein-westfalen
Germany
Kyoto
Japan
Rio-grande-do-sul
Brazil
Kanagawa
Fukushima
San-diego
California
United-states

Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis

We found no evidence of embryotoxicity or teratogenicity based on the risk of miscarriage, stillbirth, or major congenital anomalies associated with ABT during the first trimester of pregnancy. Given that treatment with artemether–lumefantrine was associated with fewer adverse pregnancy outcomes than quinine, and because of the known superior tolerability and antimalarial effectiveness of ACTs, artemether–lumefantrine should be considered the preferred treatment for uncomplicated P falciparum malaria in the first trimester.

Nuffield
Oxfordshire
United-kingdom
Japan
Tokyo
Nuffield-department-of-medicine
University-of-oxford
Centre-for-tropical-medicine
Division-of-infectious-diseases
Clinical-research-center
Worldwide-antimalarial-resistance-network

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.